权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Neuropharmacology Core

神经药理学核心

基本信息

批准号：
10604270
负责人：
Sidney S Negus
金额：
$ 28.13万
依托单位：
VIRGINIA COMMONWEALTH UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-12-01 至 2025-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10604270
关键词：
Acute Address Analgesics Animals Area Behavior Behavioral Behavioral Assay Biological Assay Brain Brain region Center Core Grants Chronic Collaborations Collection Consultations Country Data Data Analyses Development Drug abuse Effectiveness Experimental Designs Family Funding Future G-Protein-Coupled Receptors Goals Grant Human Individual Institution Investigation Laboratories Leadership Measures Mediating Methodology Methods Microdialysis Molecular Molecular Target Neuroanatomy Neuropharmacology Neurotransmitters Nucleus Accumbens Opioid Pain Pathologic Pharmaceutical Preparations Pharmacotherapy Physiological Play Postdoctoral Fellow Procedures Psychological reinforcement Receptor Signaling Recording of previous events Research Research Personnel Research Project Grants Resources Rewards Scientist Self Administration Self Stimulation Serotonin Slice Substance Use Disorder Synthesis Chemistry System Techniques Tissues Training United States National Institutes of Health Universities Ventral Tegmental Area Virginia abuse liability awake behavioral study conditioned place preference drug action drug of abuse drug reward experience graduate student in vivo innovation meetings monoamine neural neurochemistry non-drug novel pre-clinical pre-clinical assessment receptor receptor binding receptor expression receptor function reinforcer substance use treatment tool

项目摘要

Project Summary – Neuropharmacology Core The Neuropharmacology Core is a new core that proposes to serve NIH-funded investigators affiliated with the P30 grant by increasing their access to key neurochemical and behavioral methodologies that are fundamental to advancement of preclinical drug abuse research. These methodologies will include techniques to assess expression and function of receptors in both tissue homogenates and tissue slices, in vivo microdialysis techniques to assess neurotransmitter levels in target brain areas in awake and behaving animals, and behavioral techniques to assess rewarding/reinforcing effects of drugs under different physiological or environmental conditions. Although this is a new core, the investigators have decades of expertise in their respective areas and a history of collaboration both with each other and with other VCU investigators. The rationale for this core is founded on the proposition that drugs of abuse act on molecular targets to modulate activity in brain reward systems and alter behavior, and preclinical drug abuse research benefits from coordinated investigation of drug effects along the entire continuum from molecular to behavioral levels of analysis. However, individual grants typically focus on a portion of this continuum and often lack resources for rapid and rational extension of important findings to other, related research domains. As one example, a synthetic chemistry grant might identify a new molecular entity with promising analgesic effects but lack resources for preclinical assessment of that compound's abuse liability or potential utility as a treatment for substance use disorders. As another example, a grant focused on behavioral studies to treat drug abuse might identify an effective medication strategy but lack resources to investigate candidate mechanisms that underlie medication efficacy. The Neuropharmacology Core proposes to address these gaps and strengthen the breadth and impact of drug abuse research at VCU. Studies of receptor expression and function (Aim 1), in vivo microdialysis (Aim 2), and behavioral expression of reward/reinforcement (Aim 3) will enable investigators to evaluate effects of pathological states or of acute/chronic drug treatments on neural systems and behavioral endpoints known to be important in drug abuse.

项目摘要 – 神经药理学核心神经药理学核心是一个新的核心，旨在为隶属于 NIH 资助的研究人员提供服务 P30 通过增加他们获得关键神经化学和行为方法的机会来资助促进临床前药物滥用研究。这些方法将包括评估技术组织匀浆和组织切片中受体的表达和功能，体内微透析评估清醒和行为动物目标大脑区域神经递质水平的技术，以及行为技术来评估药物在不同生理或条件下的奖励/强化作用环境条件。尽管这是一个新的核心，但研究人员在其领域拥有数十年的专业知识各自的领域以及彼此之间以及与其他弗吉尼亚联邦大学研究人员的合作历史。这一核心的基本原理是基于这样的主张：滥用药物作用于分子靶点，调节大脑奖励系统的活动并改变行为，临床前药物滥用研究受益于从分子水平到行为水平的整个连续体中药物效应的协调研究分析。然而，个人赠款通常侧重于这一连续体的一部分，并且往往缺乏资源将重要发现快速合理地扩展到其他相关研究领域。作为一个例子，一个合成化学资助可能会发现一种具有良好镇痛作用但缺乏前景的新分子实体用于临床前评估该化合物的滥用倾向或作为治疗的潜在效用的资源物质使用障碍。另一个例子，专注于治疗药物滥用的行为研究的拨款可能确定有效的药物治疗策略，但缺乏资源来研究潜在的候选机制药物疗效。神经药理学核心建议解决这些差距并加强弗吉尼亚联邦大学药物滥用研究的广度和影响。受体表达和功能的研究（目标 1），体内微透析（目标 2）和奖励/强化的行为表达（目标 3）将使研究人员能够评估病理状态或急性/慢性药物治疗对神经系统和行为的影响已知对药物滥用很重要的终点。